Effect of Helicobacter Pylori Eradication on Gastroesophageal RefIux Disease (GERD)

GERD Clinical Trial

Official title:

Effect of Helicobacter Pylori Eradication on Gastroesophageal RefIux Disease (GERD)

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT06457334
• Other study ID #: H.pylori eradication on GERD
• Status: Recruiting
• Start date: January 1, 2024
• Est. completion date: January 1, 2025

Study information

• Verified date: June 2024
• Source: Assiut University
• Contact: Sara F Abdelhamid elgamal, master
• Phone: +201023524835
• Email: sarafergany139[@]gmail.com
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Evaluate the effect of H.pylori eradication on Gastroesophageal-reflux disease and symptoms improvement

Description:

HeIicobacter PyIori (H.pyIori) is a gram-negative spiral shaped bacterium that affects up to 50% of the population worldwide, with a higher prevalences in the developing countries,Gastroesophageal reflux disease (GERD) is a chronic gastrointestinal disorder characterized by the regurgitation of gastric contents into the esophagus, resulting in a significant economic burden in direct and indirect costs and adversely affects the quality of life.GERD is caused by multiple different mechanisms that can be intrinsic, structural, or both, leading to the disruption of the esophago-gastric junction barrier resulting in exposure of the esophagus to acidic gastric contents, Clinically, GERD typically manifests with symptoms of heartburn and regurgitation. It can also present in an atypical fashion with extra-esophageal symptoms such as chest pain, dental erosions, chronic cough, laryngitis, or asthma.The relationship between H. pylori and gastroesophageal reflux disease (GERD) is still unclear, and the effect of H. pylori eradication on GERD treatment is unknown.Several studies have shown the inverse relationship between the occurrence of GERD and H.pyIori infection, in particular an increased severity of the disease is documented in patients with pre-existing symptoms .It has been showed that a markedly resolution of dyspepsia in patients at whom the eradication therapy was successful when compared with subjects with a persistent infection

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 100
• Est. completion date: January 1, 2025
• Est. primary completion date: December 31, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: N/A and older

Eligibility

Inclusion Criteria:

• All patients diagnosed as GERD clinically and endscopically.

Exclusion Criteria:

• NO exclusion criteria

Related Conditions & MeSH terms

• Gastroesophageal Reflux
• GERD

Locations

Country	Name	City	State
Egypt	Alrajhi Hospital	Assiut

Sponsors (1)

Lead Sponsor	Collaborator
Assiut University

Country where clinical trial is conducted

Egypt, 

References & Publications (1)

Ceylan A, Kirimi E, Tuncer O, Turkdogan K, Ariyuca S, Ceylan N. Prevalence of Helicobacter pylori in children and their family members in a district in Turkey. J Health Popul Nutr. 2007 Dec;25(4):422-7. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Eradication of Helicobacter pylori after triple therapy	H.pylori eradication will be assessed using the endoscope	1\2024 to 12\2024
Primary	Effect of Helicobacter pylori eradication on Gastroesophageal RefIux disease (GERD) syptomes	Evaluate the effect of H.pylori eradication on Gastroesophageal-reflux disease and correlate with GERD symptoms improvement.	1\2024 to 12\2024